1. Home
  2. SPRO vs FAT Comparison

SPRO vs FAT Comparison

Compare SPRO & FAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • FAT
  • Stock Information
  • Founded
  • SPRO 2013
  • FAT 2017
  • Country
  • SPRO United States
  • FAT United States
  • Employees
  • SPRO N/A
  • FAT N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • FAT Restaurants
  • Sector
  • SPRO Health Care
  • FAT Consumer Discretionary
  • Exchange
  • SPRO Nasdaq
  • FAT Nasdaq
  • Market Cap
  • SPRO 63.0M
  • FAT 94.4M
  • IPO Year
  • SPRO 2017
  • FAT 2017
  • Fundamental
  • Price
  • SPRO $0.97
  • FAT $5.30
  • Analyst Decision
  • SPRO Buy
  • FAT
  • Analyst Count
  • SPRO 4
  • FAT 0
  • Target Price
  • SPRO $5.00
  • FAT N/A
  • AVG Volume (30 Days)
  • SPRO 247.7K
  • FAT 17.9K
  • Earning Date
  • SPRO 11-14-2024
  • FAT 03-06-2025
  • Dividend Yield
  • SPRO N/A
  • FAT 10.65%
  • EPS Growth
  • SPRO N/A
  • FAT N/A
  • EPS
  • SPRO 0.06
  • FAT N/A
  • Revenue
  • SPRO $106,455,000.00
  • FAT $606,008,000.00
  • Revenue This Year
  • SPRO N/A
  • FAT $27.15
  • Revenue Next Year
  • SPRO N/A
  • FAT $10.38
  • P/E Ratio
  • SPRO $15.29
  • FAT N/A
  • Revenue Growth
  • SPRO 37.01
  • FAT 42.38
  • 52 Week Low
  • SPRO $0.92
  • FAT $4.51
  • 52 Week High
  • SPRO $1.89
  • FAT $9.48
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 39.40
  • FAT 44.12
  • Support Level
  • SPRO $0.92
  • FAT $5.19
  • Resistance Level
  • SPRO $1.13
  • FAT $5.39
  • Average True Range (ATR)
  • SPRO 0.06
  • FAT 0.16
  • MACD
  • SPRO 0.00
  • FAT -0.01
  • Stochastic Oscillator
  • SPRO 26.16
  • FAT 23.09

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About FAT FAT Brands Inc.

FAT Brands Inc is a multi-brand restaurant franchising company. It develops, markets, acquires and manages quick service, fast casual, casual dining, and polished casual dining restaurant concepts around the world. The company operates as a franchisor of restaurants, where the company generally does not own or operate the restaurant locations but rather generates revenue by charging franchisees an initial franchise fee as well as ongoing royalties. For some of the company's brands, it also directly owns and operates restaurant locations. Its brands include Round Table Pizza, Fatburger, Johnny Rockets, Twin Peaks, and Elevation Burger among others. Geographically, the majority of the revenue for the company is generated from the United States and the rest from other countries.

Share on Social Networks: